Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Hosseini A. et al, (2025), Nature
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
The fetal specific gene LIN28B is essential for human fetal b-lymphopoiesis and initiation of KMT2A-AFF1+ infant acute lymphoblastic leukemia
Ling R. et al, (2024), Blood, 144, 199 - 199
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis
Li R. et al, (2024), Science Translational Medicine, 16
Generating human bone marrow organoids for disease modeling and drug discovery
Olijnik A-A. et al, (2024), Nature Protocols
Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Brierley CK. et al, (2023), bioRxiv
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), British journal of haematology
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2023), British journal of haematology
Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.
Rampotas A. et al, (2023), Blood
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet